Results from highly anticipated phase 3 clinical trials in gynecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain.
Reviewed by Lily Ramsey, LLMOct 17 2023 The late-breaking studies will be featured in Presidential and Proffered Paper Sessions, and could change the treatment landscape for women with these cancers. The new therapies tested delayed the time to relapse and, in some cases, lengthened survival.Professor Krishnansu S.
In one study, 68% of women who received the immunotherapy drug pembrolizumab on top of standard treatment were cancer-free at two years, compared to 57% of women allocated to placebo on top of standard treatment. A second study tested the impact of giving a combination of two different chemotherapy drugs ahead of standard treatment with chemotherapy plus radiation - a strategy called induction chemotherapy.
Related StoriesIn ovarian cancer, achieving remission is a high unmet need, as approximately 85% of patients experience recurrent disease, with almost no long-term survival after recurrence. At the ESMO Congress 2023, randomised trial data will be discussed showing that a novel targeted therapy, called senaparib, delayed the time to relapse in patients with newly diagnosed advanced disease.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Scottish independence congress: Second event to be held in OctoberBELIEVE in Scotland has announced the date for their second Scottish independence congress.
Consulte Mais informação »
A late-night Indian street food concept is coming to ManchesterEvery dish is made from scratch in their kitchens daily and customers will be able to grab a foot-long naan until 3am
Consulte Mais informação »
Claudia Winkleman makes major change to her look and Strictly fans are stunnedThe Strictly host switched up her usual monochrome uniform for Sunday's results show
Consulte Mais informação »
Tirzepatide weight-loss study shows promising resultsAfter 12 initial weeks of weight loss with intensive lifestyle intervention alone, participants in the SURMOUNT-3 study who were randomly assigned to tirzepatide for 72 weeks achieved a total mean reduction in baseline body weight of 24.3% at week 84.
Consulte Mais informação »
2024 NFL Draft QB Tracker: Drake Maye’s QB1 case; Michael Penix Jr. delivers lateNorth Carolina's star QB deserves just as much No. 1 pick consideration as Caleb Williams, who struggled in a loss to Notre Dame.
Consulte Mais informação »